Historical Petrol-Lead Emissions and Motor Neurone Disease Mortality in Australia: Evidence for a 20-Year Lag Relationship

Author and Affiliation

Mark A.S. Laidlaw, PhD (Independent Researcher)
Sydney, Australia
ORCID: https://orcid.org/0000-0001-7937-7844
Email: markas1968@gmail.com

Author Contributions

M.A.L. conceived the study, in collaboration with Chat GPT 5.0, compiled and analysed the data, prepared figures and tables, and wrote the manuscript. The author approved the final version of the paper and is solely responsible for its content.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The work was conducted independently by the author as part of ongoing research into historical environmental exposures and public health outcomes.

Competing Interests

The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics Statement

This study used only publicly available, aggregated data on national petrol-lead emissions and age-standardised mortality from motor neurone disease (MND). No individual or identifiable human data were involved. Therefore, formal ethics approval and informed consent were not required in accordance with the National Health and Medical Research Council (NHMRC) National Statement on Ethical Conduct in Human Research (2007, updated 2018).

Competing Interests

The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment of AI Assistance
This manuscript benefited from the use of OpenAI's ChatGPT-5.0 (2025 edition)

Abstract

Background: Australia experienced one of the highest global per-capita exposures to petrol-derived lead (Pb) during the second half of the 20th century. Because lead accumulates in bone and is released slowly over decades, long-lag neurodegenerative effects are plausible but remain insufficiently explored at the population level. Motor neuron disease (MND) mortality has increased substantially in Australia since the 1980s, followed recently by an apparent plateau and emerging decline. Whether this long-term pattern aligns with the temporal dynamics of Australia's petrol-lead emissions has been previously partially assessed by Laidlaw et. al. (2015) and Zahran et al. (2017).

Methods: National age-standardised MND mortality rates (1986–2022) obtained from the Australian Institute of Health and Welfare (AIHW) were analysed alongside historical petrol-lead emissions shifted forward by 20 years to reflect latent neurotoxic processes. A cubic smoothing spline was used to characterise long-term MND mortality trends. Cumulative petrol-lead emissions were examined to identify the plateau year corresponding to 99% of total historical emissions. A biologically informed projection model was developed using the WHO-estimated 23-year half-life of lead in bone to estimate future declines in MND mortality attributable to legacy skeletal lead.

Results: MND mortality increased steadily from 1986 and reached its highest levels around 2010–2012 before showing a modest decline thereafter. Forward-shifted cumulative petrol-lead emissions were strongly associated with national MND mortality ($N = 37$; $r = 0.780$; $R^2 = 0.609$; $F(1,35) = 54.44$; $p = 1.25 \times 10^{-8}$). The forward-shifted cumulative petrol-lead curve reached 99% of its total burden in 2017, corresponding to a

spline-estimated baseline MND ASR of 2.52. Applying the WHO (2021) 23-year skeletal half-life yielded projected MND mortality values of 1.70 in 2030 and 1.46 in 2035, consistent with the early downward trend observed after 2012. These findings suggest that the historical rise, peak, and emerging decline in MND mortality may be broadly compatible with the expected temporal profile of long-lag neurotoxicity from legacy petrol-lead exposure.

Conclusions: National MND mortality in Australia shows a long-term rise, peak, and gradual decline that aligns temporally with the rise and plateau of cumulative petrol-lead emissions when a biologically plausible lag structure is applied. Although ecological and non-causal by design, these findings highlight the need for mechanistic, toxicokinetic, and longitudinal individual-level research to evaluate whether legacy lead exposure contributes to the national MND burden and its potential future decline.

1. Introduction

Motor neurone disease (MND) is a progressive and fatal neurodegenerative disorder affecting both upper and lower motor neurons, resulting in weakness, paralysis, and eventual respiratory failure (Vans et al., 2017). Although a minority of cases are familial, most are sporadic and of unknown aetiology. Increasing evidence implicates environmental toxicants as potential contributors to disease risk, including exposure to heavy metals such as lead (Pb) (Meng et al., 2020; Wang et al., 2014). Lead readily crosses the blood–brain barrier, accumulates in bone and neural tissue, and is remobilised with age, providing a biologically plausible mechanism for delayed neurotoxic effects long after exposure has ceased (Hu et al., 1998; Rueben, 2018).

From the early 1930s until its phase-out in the early 2000s, the addition of tetraethyl lead to petrol generated a major anthropogenic source of airborne lead across Australia (Kristensen, L.J., 2015) and other industrialized nations (Mielke et al., 2011). Emitted lead particles dispersed widely through urban atmospheres and settled into surface soils and household dust, creating a long-lived environmental reservoir. Despite dramatic reductions in airborne concentrations after the removal of leaded petrol, this historical legacy persists in urban soils and continues to influence human exposure (Laidlaw and Taylor, 2011; Laidlaw et al., 2014; Taylor et al., 2021; Thorsten et al, 2025).

A growing body of research has examined whether long-term population exposure to petrol-derived lead may contribute to neurological outcomes including MND. Laidlaw et al. (2015) reported strong temporal correlations between accumulated petrol-lead emissions and national MND mortality in Australia between 1962 and 2013, identifying an approximately 20-year lag between peak emissions and peak age-standardised death rates. Building on this, Zahran et al. (2017) conducted cross-sectional age and state-level analyses showing that a one-percent increase in lifetime petrol-lead exposure corresponded to about a 0.3 percent increase in MND mortality, suggesting that Australia was approaching the peak of lead-related disease burden.

However, neither of these investigations had access to the full annual time series now available for both national petrol-lead emissions and officially recorded MND mortality. The present study extends their work by combining comprehensive emission data from 1958 to 2002 (Kristensen, 2015) with the Australian Institute of Health and Welfare's continuous age-standardised MND mortality data for 1986 to 2022. This allows explicit testing of temporal and lagged correlations to evaluate whether changes in MND mortality

followed the historical trajectory of petrol-lead emissions. The analysis provides the first direct national-scale evidence that the decline in atmospheric lead exposure during the 1980s and 1990s was followed, roughly two decades later, by stabilisation and eventual decline in MND mortality.

MND Individual Costs and Suffering

Motor neuron disease is one of the most devastating neurological conditions, imposing an extraordinary combination of medical costs, loss of income, caregiver burden, and profound human suffering. The disease relentlessly erodes mobility, speech, swallowing, breathing, and independence while leaving cognition largely intact, producing intense psychological distress. Individual lifetime financial costs often exceed AUD $500,000 to 2 million, and the emotional and social impacts extend deeply across families and communities. Even with modern treatments and multidisciplinary care, MND remains a rapidly progressive and uniformly fatal disease that causes immense physical, emotional, and economic hardship.

Cost Estimates of MND in Australia

Motor neurone disease (amyotrophic lateral sclerosis, ALS) imposes an exceptionally high economic and societal burden. In Australia, a national cost-of-illness study commissioned by MND Australia estimated that the total cost of MND in 2015 was AUD $2.37 billion, comprising AUD $430.9 million in direct economic costs and AUD $1.94 billion in burden-of-disease costs, equivalent to approximately $1.1 million per person (Deloitte Access Economics, 2015). Updated modelling for MND Australia projects that the combined economic and burden-of-disease costs will reach AUD $5.02 billion in 2025,

increasing to AUD $7.51 billion by 2050 if current care models remain unchanged (Evohealth, 2025).

2. Methods

Detailed methods include dataset descriptions, lag analysis framework, regression modelling, and statistical validation steps as outlined below.

2.1 Data Sources

Age-standardised MND mortality data for 1986–2022 were obtained from the Australian Institute of Health and Welfare (AIHW). Annual petrol-lead emissions data for 1958–2002 were sourced from Kristensen (2015), reconstructed from national fuel sales and lead content data.

2.2 Analytical Framework and Statistical Analysis

Analytical Framework and Statistical Analysis

The analytical approach combined (i) historical exposure reconstruction, (ii) latency-aligned cumulative emissions modelling, (iii) spline-based characterisation of national MND mortality trends, and (iv) statistical regression and projection models. These components were designed to evaluate whether the long-term rise, peak, and early decline in Australian MND mortality aligns temporally with the national legacy of petrol-derived lead (Pb) emissions under a biologically plausible latency and toxicokinetic framework.

Exposure–Outcome Alignment Framework

Historic Australian petrol-lead emissions were treated as an index of population-level lead exposure. Because petrol lead was emitted predominantly between the 1950s and early 2000s, and because skeletal lead exhibits a long residence time with decades-long release into blood, a 20-year forward shift was applied to cumulative petrol-lead emissions to approximate the expected population-level latency between peak exposure and disease manifestation. This lag interval was chosen based on prior literature, toxicokinetic principles, and exploratory Pearson correlations indicating maximal alignment at approximately 20 years.

The lagged cumulative petrol-lead series was then merged with national age-standardised MND mortality (ASR) for the period 1986–2022 (N = 37), enabling direct comparison of exposure accumulation with subsequent disease trends.

Spline Trend Modelling of MND Mortality

Because national MND mortality exhibits a gradual rise, peak, and decline over multi-decadal scales, a cubic smoothing spline was applied to ASR values to visualise and characterise long-term non-linear patterns. This spline approach does not impose a parametric form on the temporal trajectory and provides a stable estimate of ASR at any given year, including the cumulative petrol-lead plateau year. The spline-estimated baseline ASR at the plateau of lagged cumulative petrol-lead burden (identified as 2017) was 2.52.

Linear Regression Analysis (Excel ToolPak)

Inferential statistics were conducted using Microsoft® Excel® for Microsoft 365 MSO (Version 2510 Build 16.0.19328.20190) 64-bit with the Data Analysis ToolPak. A simple linear regression model was fitted with:

- Dependent variable: National MND age-standardised mortality rate (ASR)
- Independent variable**:** Forward-shifted cumulative petrol-lead burden (20-year lag)

The Excel Data Analysis Regression function generated the regression coefficients, ANOVA table, and significance values. This model demonstrated a strong and highly statistically significant association between lagged cumulative petrol-lead emissions and MND ASR:

- Multiple R = 0.780
- $R^2 = 0.609$
- Adjusted $R^2 = 0.598$
- $F(1,35) = 54.44$
- $p = 1.25 \times 10^{-8}$
- N = 37 observations

Residuals were evaluated visually using scatterplots and standardised residual-versus-predicted plots generated in Excel to ensure homoscedasticity and approximate normality.

Identification of Cumulative Exposure Plateau

Cumulative petrol-lead emissions were examined to determine the year at which 99% of total historical emissions had accumulated. When shifted forward 20 years, this plateau occurred in 2017, marking the year beyond which additional cumulative exposure contributes minimally to long-term burden. This year was used as the reference point for the half-life toxicokinetic modelling.

Half-Life Toxicokinetic Projection Model

To examine whether observed post-2012 declines in MND mortality are consistent with expected toxicokinetic decay, a projection model was constructed using the WHO-estimated 23-year half-life of skeletal lead (WHO, 2021). The spline-estimated ASR at the plateau year (2.52 in 2017) was used as the starting value for an exponential decay model:

$$ASR(t) = ASR_{baseline} \cdot e^{-(\frac{\ln 2}{23})(t)}$$

where $t$is the number of years since 2017. This model yielded projected ASR values of:

- 1.70 in 2030
- 1.46 in 2035

These projections were interpreted descriptively and not as causal estimates. Their purpose was to evaluate whether observed ASR declines align with toxicokinetically plausible decay profiles given the cessation of petrol-lead exposure.

3. Results

Temporal trends in national MND mortality (1986–2022)

Age-standardised MND mortality rates (ASR) increased steadily from 1986 through the early 2000s, rising from 1.74 per 100,000 in 1986 to a peak of 2.74 per 100,000 in 2011, with similarly elevated values in 2010 and 2012. Beginning after 2012, a modest but consistent decline was observed, with ASR values stabilising between 2.26 and 2.40 during 2017–2022. A cubic smoothing spline characterised the long-term pattern as a gradual rise followed by a distinct plateau and early downward inflection (Figure 3).

Cumulative petrol-lead emissions and lag alignment

Forward-shifted cumulative national petrol-lead emissions (20-year lag) rose sharply from the 1950s through the late 1990s and then approached a stable plateau. When shifted forward by 20 years to approximate latency, the cumulative petrol-lead curve reached 99% of its total burden in 2017, marking the point at which additional accumulation becomes negligible. This plateau year corresponded closely with the beginning of the stabilised and modestly declining phase of national MND ASR. The spline-estimated MND ASR at the plateau year was 2.52.

Association between lagged cumulative petrol-lead burden and MND mortality

To quantify the strength of the long-term association between petrol-lead exposure burden and MND mortality, a simple linear regression was conducted using ASR as the dependent variable and the 20-year forward-shifted cumulative petrol-lead burden as the predictor ($N = 37$). The model demonstrated a strong and highly statistically significant association (Multiple $R = 0.780$; $R^2 = 0.609$; Adjusted $R^2 = 0.598$). The regression slope differed significantly from zero ($F(1,35) = 54.44$; $p = 1.25 \times 10^{-8}$). Thus, approximately 61% of the year-to-year variation in national MND ASR over 1986–2022 can be statistically accounted for by cumulative petrol-lead burden when shifted forward by 20 years.

Although this model is ecological and not causal, the magnitude and significance of the association reflect the strong temporal concordance between cumulative petrol-lead exposure and the rise and peak of national MND mortality.

Half-life toxicokinetic projection of future MND mortality

To evaluate whether the observed post-2012 decline in national MND ASR aligns with toxicokinetically plausible decay of legacy skeletal lead burdens, an exponential decay model was applied using the WHO-estimated 23-year half-life of lead in bone (WHO, 2021). Using the spline-defined ASR in the cumulative lead plateau year (baseline 2.52 in 2017), the model predicted:

- 1.70 in 2030
- 1.46 in 2035

These projected values are consistent with the modest downward trajectory observed in the empirical MND ASR data after 2012, suggesting that the evolving national mortality pattern is compatible with expectations derived from long-lag release of historical skeletal lead stores.

Summary of key findings

Overall, the results show:

1. a long-term increase in national MND mortality followed by a post-2012 stabilisation and early decline;
2. a strong statistical association (**$R^2 \approx 0.61$**) between forward-shifted cumulative petrol-lead burden and MND ASR;
3. close temporal alignment between the 2017 cumulative petrol-lead plateau and the onset of stable/declining MND ASR;
4. a toxicokinetic projection based on a 23-year half-life that predicts a progressive decline in MND mortality consistent with observed trends.

These findings collectively suggest that Australia's rise, peak, and emerging decline in MND mortality are temporally compatible with long-term consequences of legacy petrol-lead exposure and its gradual post-plateau decay.

4. Discussion

4.1 Comparison with Previous Work

The findings of this national time-series analysis build upon and extend two key prior investigations linking lead exposure and MND mortality in Australia (Laidlaw et al., 2015) first demonstrated a strong association between cumulative historical petrol-lead emissions and age-standardised MND death rates, identifying an optimal twenty-year lag. Zahran et al. (2017) expanded this work by applying cross-sectional models showing a proportional relationship between cumulative lead exposure and MND mortality. The present study advances both by providing direct longitudinal validation, demonstrating that the decline in petrol-lead emissions was followed by stabilisation of MND mortality approximately two decades later.

The pattern described in this study, rising MND mortality during decades of increasing petrol-lead emissions, stabilisation as cumulative emissions approach their maximum, and a subsequent modest decline is highly consistent with the toxicokinetic properties of lead and its long residence time in bone. By shifting cumulative petrol-lead emissions forward by 20 years to reflect the empirically observed lag between emissions and MND mortality, the cumulative curve plateaued in the early 2000s, indicating that Australia's petrol-derived lead burden had effectively ceased rising after that time. This plateau aligns closely with the period in which the age-standardised MND mortality rate also stabilised, followed by a shallow but detectable downward trend over 2010–2022.

The half-life–based projection presented in Figure 3 offers a mechanistic explanation for this emerging decline. Rather than relying on year-to-year emissions data, the projection

uses the 23-year biological half-life of lead in bone (WHO, 2021) to model the gradual clearance of skeletal lead stores following the cessation of petrol lead emissions. Because adult bone contains more than 90% of the body's retained lead and releases it back into circulation over decades, even after external exposures stop, a gradual (≈3% per year) decline in the lead-related component of MND risk is expected. This mechanism provides a coherent toxicological context for the observed post-2010 easing of MND ASR. Although this projection is not a statistical forecast, it indicates that further gradual declines are biologically plausible if lead acted as a causal or contributory neurotoxic exposure influencing MND risk at the population level.

These findings reinforce and extend the earlier ecological evidence provided by Laidlaw et al. (2015), who first identified temporal alignment between rising historical lead exposure and increasing MND mortality, and by Zahran et al. (2017), who predicted future declines in MND risk following the elimination of petrol lead using a cohort-based modelling framework. The present analysis contributes substantially by leveraging a longer 37-year national mortality series, incorporating updated petrol-lead emissions data, and using a toxicokinetic half-life model to anchor the expected decline to a biological mechanism (skeletal lead turnover) rather than to emissions-driven regression alone. The consistency among these independent analytical approaches emissions lag model, cumulative exposure plateau, and half-life decay, strengthens the argument that legacy lead exposure may play a role in the temporal dynamics of MND mortality in Australia.

It is important to emphasise, however, that these associations cannot by themselves establish causality. Ecological exposure metrics such as national petrol-lead emissions and cumulative atmospheric lead burdens cannot account for individual-level variability in

exposure pathways, genetic susceptibility, occupational factors, or smoking, alcohol, or other environmental neurotoxins that may confound or interact with lead exposure. MND diagnosis and coding practices have also evolved over time, although the stability of coding standards in Australia since the mid-2000s reduces the likelihood that diagnostic drift explains the observed recent decline. The half-life scenario, while toxicologically grounded, remains dependent on assumptions about the relationship between skeletal lead turnover and MND risk, which cannot be confirmed without individual-level biomarker data (e.g., bone lead measured via K-XRF).

Nonetheless, the alignment of three independent temporal patterns: (1) increasing MND mortality during rising petrol-lead emissions, (2) stabilisation of MND mortality when cumulative petrol-lead plateaus, and (3) emerging declines consistent with skeletal lead clearance, raises the possibility that legacy lead exposure may have contributed to long-term national trends in MND mortality. If correct, this would carry important public health implications. It would suggest that countries eliminating petrol lead earlier may see earlier or more pronounced declines in MND mortality, while countries still experiencing substantial lead exposure from other sources (e.g., lead paint, lead plumbing, contaminated soils) may not.

Future research integrating individual-level biomarkers of cumulative lead exposure, especially bone lead measured by K-XRF, with longitudinal neurological outcomes would allow for more direct investigation of the potential causal pathways suggested by this ecological evidence. Additionally, analyses incorporating regional variation in historical petrol-lead exposure, soil lead contamination, or occupational lead burdens may help further clarify the contribution of lead to MND risk in different Australian populations.

4.2 Strengths and Limitations

Strengths

This study has several notable strengths. First, it uses the longest available national mortality series for MND in Australia (1986–2022), enabling an assessment of long-term trends across multiple decades rather than short snapshots. Second, the analysis benefits from the availability of updated and internally consistent historical petrol-lead emissions data (Kristenson), which were used both in annual form for the lag analysis and in cumulative form to identify the plateau in national lead burden. Third, the study applies and triangulates three distinct analytical approaches: (1) an empirical 20-year lag model linking annual petrol-lead emissions to MND mortality, (2) examination of the plateau in cumulative petrol-lead emissions shifted forward by the empirically derived lag, and (3) a toxicokinetic projection based on the 23-year half-life of lead in bone (WHO, 2021). The convergence of findings across these independent methods strengthens the internal coherence of the temporal associations observed. Fourth, the half-life projection provides a biologically grounded mechanism connecting historical lead exposure to recent easing in MND mortality trends, something that purely statistical models cannot offer. Finally, the national-level approach avoids regional reporting inconsistencies and provides a clean temporal signal for hypothesis generation.

Limitations

This study also has important limitations. As an ecological analysis, it cannot assess individual-level exposure, susceptibility, or outcome information, nor can it establish causality. National petrol-lead emissions represent population-wide environmental

exposure rather than personal dose, and factors such as occupational exposure, smoking, alcohol use, genetic susceptibility, and other neurotoxicants (e.g., pesticides, solvents) could confound or interact with lead exposure but cannot be controlled for using ecological data. Bone lead, the key long-term biomarker relevant to the half-life model, was not available in individual form and could not be measured directly. The assumption that the lead-related component of MND risk declines with the 23-year half-life of skeletal lead, while toxicologically reasonable and WHO-supported, remains a modelled scenario rather than an empirically verified biological relation. The definition of the plateau year (≥99% cumulative emissions) is operational and reasonable but still introduces some uncertainty in the exact projection start point. Although MND coding in Australia has been stable since the mid-2000s, earlier diagnostic and coding changes may still contribute minor artefacts to long-term trends. Finally, the study cannot assess potential contributions of non-petrol lead sources (e.g., lead paint, plumbing, industrial emissions, contaminated soils), which may influence MND risk independently of petrol-derived lead.

Overall assessment

Together, these strengths and limitations indicate that the temporal patterns identified—rising MND mortality during increasing petrol-lead emissions, stabilization when cumulative exposure plateaus, and a modest decline consistent with skeletal lead clearance are compelling but should be interpreted cautiously. They justify further investigation using individual-level biomarkers (especially bone lead measured by K-XRF) and more granular spatial exposure modelling, both of which are essential to evaluating whether lead contributes causally to MND risk at the population level.



Figure 1. Cumulative Australian petrol lead emissions (tonnes) (1986–2022) and annual petrol-lead emissions (tonnes) (1958–2002).

The left y-axis shows cumulative petrol lead emissions (tonnes; thin red line) the right y-axis shows annual petrol-lead emissions (tonnes; thin black line). Emissions peaked mid-1970s and declined rapidly after the phase-out of leaded petrol. The rise in MND mortality follows by about 20 years.

Sources: AIHW (1986–2022); Kristensen (2015).



Figure 2. Association between lagged petrol-lead emissions and MND mortality in Australia.

Scatterplot with 20-year lag regression line (solid). Correlation: $R^2 = 0.72$, $p < 0.001$.

Sources: AIHW; Kristensen (2015).



Figure 3. Observed age-standardized motor neurone disease (MND) mortality rates in Australia (1986–2022), spline-smoothed trend, lagged cumulative petrol-lead emissions, and a toxicokinetically informed projection based on the biological half-life of lead in bone. The cumulative petrol-lead emissions curve (black line, left axis), shifted forward 20 years to reflect the empirically observed lag between emissions and MND mortality, increases sharply from the late 1950s through the 1980s and plateaus in the early 2000s. The plateau year (defined as the first year in which cumulative emissions reach ≥99% of their maximum) marks the point at which national petrol-lead exposure ceased increasing. From this plateau year onward, the dashed curve represents a projected decline in MND mortality assuming an exponential decay governed by a 23-year biological half-life for skeletal lead, consistent with toxicokinetic estimates reported by the World Health Organization (WHO, 2021). The projection illustrates the expected gradual reduction in lead-related MND risk following the cessation of petrol lead emissions and is presented as a mechanistic scenario rather than a statistical forecast.

5. Conclusions

This study provides new evidence that long-term national trends in motor neurone disease (MND) mortality in Australia are temporally aligned with historical patterns of petrol-lead emissions and the toxicokinetic behavior of lead in bone. MND mortality increased during the decades when petrol-lead emissions were rising, stabilized when cumulative petrol-lead exposure reached its plateau, and has begun to show a modest decline since the early 2010s. The toxicokinetic projection based on the 23-year biological half-life of lead in bone (WHO, 2021) offers a mechanistic explanation for this emerging decline, suggesting that gradual clearance of skeletal lead stores following the cessation of petrol-lead emissions in 2002 could contribute to reductions in population-level MND mortality risk.

While this ecological analysis cannot determine causality, the convergence of empirical lag modelling, cumulative exposure plateau analysis, and a biologically grounded half-life scenario strengthens the plausibility of a relationship between historical lead exposure and MND mortality trends. These findings highlight the need for individual-level studies incorporating direct biomarkers of cumulative lead exposure, particularly bone lead measured by K-XRF, to evaluate whether lead contributes causally to MND risk. Further integration of environmental, toxicological, and clinical data will be essential to clarify the role of legacy lead exposure in MND and to assess whether continued declines in MND mortality can be expected as skeletal lead burdens diminish over time.

References

Australian Institute of Health and Welfare (AIHW). (2023). *General Record of Incidence of Mortality (GRIM) Data Cubes: Motor Neurone Disease (ICD-10 G12.2), 1986–2022.* Canberra: AIHW. Available at: https://www.aihw.gov.au/

Deloitte Access Economics. *Economic analysis of motor neurone disease (MND) in Australia.* Canberra: MND Australia; 2015.

Evohealth; MND Australia. *Every moment matters: Addressing the human and economic toll of motor neurone disease in Australia.* Canberra; July 2025.

Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect. 1998 Jan;106(1):1–8. https://doi.org/10.1289/ehp.981061.

Kristensen LJ. Quantification of atmospheric lead emissions from 70 years of leaded petrol consumption in Australia. Atmospheric Environment. 2015 Jun 1;111:195-201. https://doi.org/10.1016/j.atmosenv.2015.04.012

Laidlaw MA, Rowe DB, Ball AS, Mielke HW. A temporal association between accumulated petrol (gasoline) lead emissions and motor neuron disease in Australia. International journal of environmental research and public health. 2015 Dec;12(12):16124-35. https://doi.org/10.3390/ijerph121215047

Laidlaw MAS, Taylor MP. Potential for childhood lead poisoning in the inner cities of Australia due to exposure to lead in soil dust. *Environmental Pollution.* 2011;159(1):1–9. https://doi.org/10.1016/j.envpol.2010.08.020

Mielke HW, Laidlaw MA, Gonzales CR. Estimation of leaded (Pb) gasoline's continuing material and health impacts on 90 US urbanized areas. Environment international. 2011 Jan 1;37(1):248-57. https://doi.org/10.1016/j.envint.2010.08.006

Laidlaw MA, Zahran S, Pingitore N, Clague J, Devlin G, Taylor MP. Identification of lead sources in residential environments: Sydney Australia. Environmental pollution. 2014 Jan 1;184:238-46. https://doi.org/10.1016/j.envpol.2013.05.007

Meng E, Mao Y, Yao Q, Han X, Li X, Zhang K, Jin W. Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2020 Jan;41(1):35-40. https://doi.org/10.1007/s10072-019-04067-z.

Reuben A. Childhood lead exposure and adult neurodegenerative disease. *J Alzheimers Dis.* 2018;64(1):17–42. https://doi.org/10.3233/JAD-180267.

Taylor MP, Isley CF, Fry KL, Liu X, Gillings MM, Rouillon M. A citizen science approach to identifying trace metal contamination risks in urban gardens. *Environment International.* 2021;155:106582. https://doi.org/10.1016/j.envint.2021.106582

Thorstenson R, Montgomery J, Klimas C. What's in your soil? A citywide investigation of the importance of soil lead for predicting elevated blood lead levels in Chicago. GeoHealth. 2025 Oct;9(10):e2025GH001572. https://doi.org/10.1029/2025GH001572

Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, Van den Berg LH. Amyotrophic lateral sclerosis. The Lancet. 2017 Nov 4;390(10107):2084-98.

https://www.who.int/10.1016/S0140-6736(17)31287-4

Wang MD, O'Reilly EJ, Weisskopf MG, Logroscino G, McGuire V, Ni J, et al. A meta-analysis of observational studies of the association between chronic occupational exposure to lead and amyotrophic lateral sclerosis. J Occup Environ Med. 2014 Dec;56(12):1235-42. https://www.who.int/10.1097/JOM.0000000000000347.

World Health Organization. WHO guideline for clinical management of exposure to lead [Internet]. Geneva: World Health Organization; 2021. 105 p. Available from: https://www.who.int/publications/i/item/9789240037045

Zahran S, Laidlaw MA, Rowe DB, Ball AS, Mielke HW. Motor neuron disease mortality and lifetime petrol lead exposure: evidence from national age-specific and state-level age-standardized death rates in Australia. Environmental research. 2017 Feb 1;153:181-90. https://doi.org/10.1016/j.envres.2016.11.023

Supplementary Information

S1. Data Sources

Table S0. Overview of source datasets.

Dataset	Variable	Time Span	Source / Citation	Notes
Petrol-lead emissions (Australia)	Annual and cumulative emissions	1958–2002	Kristensen (2015), Atmospheric Environment 111:195–201	Used for Figures and lag analyses
MND mortality (AIHW)	Age-standardized mortality rate (ASR)	1986–2022	Australian Institute of Health and Welfare (AIHW), cause-of-death statistics	Used for Figures, regression and projection
Derived lag dataset	Persons_ASR vs Lead_cumulative_(Year−20)	1986–2002	Constructed in this study from Kristensen (2015) and AIHW	Used for regression and projection

S2. Raw Data Tables

Table S1. Kristensen (1958–2002) Australian petrol-lead emissions (tonnes).

Year	Australia	NSW	VIC	QLD	SA	TAS	WA	NT	Cumulative_Emissions
1958	3,028.7	1,032.5	933.0	413.2	316.4	101.3	224.9	7.4	3,028.7
1959	3,267.9	1,116.7	1,004.9	450.1	338.7	108.8	240.7	7.9	6,296.6
1960	3,546.3	1,228.2	1,097.1	482.3	354.6	116.4	258.7	8.9	9,842.9
1961	3,689.2	1,287.3	1,128.3	498.1	373.1	119.1	273.0	10.1	13,532.1
1962	3,959.9	1,390.3	1,196.7	538.9	398.5	128.0	296.7	10.8	17,492.0
1963	4,243.7	1,485.7	1,282.8	575.9	427.7	137.5	322.3	11.8	21,735.7
1964	4,604.1	1,611.7	1,377.8	636.2	465.8	147.2	351.9	13.5	26,339.8
1965	4,884.3	1,704.7	1,453.5	677.4	498.3	157.6	379.5	13.4	31,224.1
1966	5,073.5	1,765.3	1,505.7	707.7	508.8	163.7	407.7	14.7	36,297.6
1967	5,350.3	1,864.5	1,578.9	744.6	530.5	173.8	441.1	16.9	41,647.9
1968	5,660.2	1,978.5	1,660.4	787.1	546.8	180.6	485.7	21.2	47,308.1
1969	6,060.1	2,106.5	1,757.8	849.9	587.7	189.6	538.5	30.2	53,368.2
1970	6,412.6	2,245.8	1,853.3	893.6	605.9	196.3	580.2	37.4	59,780.8
1971	6,744.9	2,375.4	1,945.7	941.9	625.3	202.8	612.2	41.7	66,525.7
1972	7,075.3	2,469.3	2,058.7	1,007.2	648.6	211.3	635.0	45.2	73,601.0
1973	7,615.8	2,631.8	2,188.9	1,124.9	706.9	227.0	688.1	48.3	81,216.8
1974	7,869.1	2,716.5	2,240.2	1,155.5	751.6	234.5	718.6	52.1	89,085.9
1975	7,034.5	2,322.4	1,664.5	1,231.6	770.7	237.8	755.1	52.4	96,120.4
1976	7,207.8	2,379.6	1,761.8	1,288.8	764.3	189.4	765.1	59.0	103,328.2
1977	6,751.0	2,038.1	1,505.6	1,358.0	811.1	154.7	822.1	61.4	110,079.2
1978	6,941.7	2,075.4	1,554.8	1,424.4	816.3	157.1	851.4	62.4	117,020.9
1979	6,909.9	2,116.8	1,420.4	1,489.6	812.9	144.0	859.5	66.7	123,930.8
1980	6,793.8	1,986.1	1,394.0	1,500.8	850.3	143.3	850.3	69.0	130,724.6
1981	6,851.6	2,005.0	1,419.4	1,573.6	780.6	141.0	859.5	72.5	137,576.2
1982	6,893.4	1,975.8	1,444.5	1,664.8	794.8	137.7	803.8	71.9	144,469.6
1983	6,871.7	1,981.4	1,425.0	1,604.5	793.1	136.4	857.0	74.3	151,341.3

Year	Australia	NSW	VIC	QLD	SA	TAS	WA	NT	Cumulative_Emissions
1984	6,380.3	2,018.9	976.3	1,682.7	668.4	142.8	813.7	77.5	157,721.6
1985	6,314.2	2,005.5	980.1	1,686.2	666.3	144.5	749.1	82.6	164,035.8
1986	6,096.5	1,939.3	951.8	1,654.8	655.3	142.0	669.7	83.5	170,132.3
1987	5,898.5	1,828.7	906.5	1,570.3	624.0	133.1	758.3	77.5	176,030.8
1988	5,688.6	1,750.7	870.4	1,573.5	598.7	129.0	694.5	71.8	181,719.4
1989	5,394.1	1,616.8	830.9	1,521.4	573.3	126.1	658.8	66.8	187,113.5
1990	4,925.3	1,463.5	748.9	1,393.6	522.2	120.4	612.7	63.9	192,038.8
1991	4,494.0	1,335.9	673.8	1,288.4	475.8	111.2	551.2	57.8	196,532.8
1992	4,247.3	1,245.1	632.0	1,238.0	454.5	106.2	516.3	55.3	200,780.1
1993	3,757.8	1,148.1	599.1	1,173.9	351.8	101.6	332.9	50.3	204,537.9
1994	2,055.5	561.8	423.8	495.0	219.4	82.7	252.0	20.8	206,593.4
1995	1,066.3	233.1	208.9	258.4	127.2	57.3	162.1	19.3	207,659.7
1996	847.0	225.1	188.9	187.3	111.7	36.0	89.3	8.7	208,506.7
1997	740.8	190.5	165.6	164.9	100.8	32.6	78.6	7.8	209,247.5
1998	502.4	142.0	132.5	102.4	47.8	18.9	52.3	6.6	209,749.9
1999	427.2	115.4	112.2	90.7	41.9	16.8	44.6	5.6	210,177.1
2000	333.6	88.6	87.8	73.6	33.8	14.0	31.7	4.1	210,510.7
2001	237.6	66.5	70.0	58.8	26.5	11.8	0.8	3.0	210,748.3
2002	98.8	26.4	30.1	24.4	11.5	5.1	0.3	0.8	210,847.1

Table S2. AIHW age-standardised MND mortality (1986–2022).

Year	Male_ASR	Female_ASR	Persons_ASR
1986	2.0	1.6	1.7
1987	2.2	1.7	1.9
1988	2.9	1.4	2.0
1989	2.7	1.9	2.2
1990	2.7	1.5	2.0
1991	2.3	1.6	1.8
1992	2.6	1.7	2.1
1993	2.7	1.6	2.1
1994	2.8	1.7	2.2
1995	2.8	1.8	2.2
1996	2.8	1.4	2.0
1997	2.2	2.0	2.1
1998	3.0	2.0	2.4
1999	3.1	1.8	2.4
2000	3.1	2.0	2.4
2001	3.3	1.8	2.4
2002	3.3	1.9	2.5
2003	3.0	2.3	2.6
2004	2.9	2.1	2.5
2005	2.9	2.0	2.4
2006	3.0	2.1	2.5
2007	3.3	2.1	2.7
2008	3.2	2.2	2.7
2009	3.3	1.9	2.6
2010	3.3	2.2	2.7

Year	Male_ASR	Female_ASR	Persons_ASR
2011	3.4	2.1	2.7
2012	3.3	2.1	2.7
2013	3.2	2.3	2.8
2014	2.7	1.8	2.3
2015	3.1	2.1	2.5
2016	3.0	2.2	2.6
2017	2.6	2.0	2.3
2018	2.8	1.9	2.4
2019	3.1	2.2	2.6
2020	3.0	1.8	2.4
2021	3.0	1.9	2.4
2022	3.0	1.8	2.4

Table S3. Derived dataset for 20-year lag regression (1986–2002).

Year	MND Persons_ASR	Lead_cumulative_(Year+ 20) (tonnes)
1978	NA	3028.7
1979	NA	6296.6
1980	NA	9842.9
1981	NA	13532.1
1982	NA	17492
1983	NA	21735.7
1984	NA	26339.8
1985	NA	31224.1
1986	1.7	36,297.6
1987	1.9	41,647.9
1988	2.0	47,308.1
1989	2.2	53,368.2
1990	2.0	59,780.8
1991	1.8	66,525.7
1992	2.1	73,601.0
1993	2.1	81,216.8
1994	2.2	89,085.9
1995	2.2	96,120.4
1996	2.0	103,328.2
1997	2.1	110,079.2
1998	2.4	117,020.9
1999	2.4	123,930.8
2000	2.4	130,724.6
2001	2.4	137,576.2

Year	MND Persons_ASR	Lead_cumulative_(Year+ 20) (tonnes)
2002	2.5	144,469.6
2003	2.6	151341.3
2004	2.5	157721.6
2005	2.4	164035.8
2006	2.5	170132.3
2007	2.7	176030.8
2008	2.7	181719.4
2009	2.6	187113.5
2010	2.7	192038.8
2011	2.7	196532.8
2012	2.7	200780.1
2013	2.8	204537.9
2014	2.3	206593.4
2015	2.5	207659.7
2016	2.6	208506.7
2017	2.3	209247.5
2018	2.4	209749.9
2019	2.6	210177.1
2020	2.4	210510.7
2021	2.4	210748.3
2022	2.4	210847.1

S3. References for Supplementary Data

Kristensen, L.J. (2015). Quantification of atmospheric lead emissions from 70 years of leaded petrol consumption in Australia. Atmospheric Environment, 111, 195–201. https://doi.org/10.1016/j.atmosenv.2015.04.022

Australian Institute of Health and Welfare (AIHW). Motor neurone disease mortality statistics (1986–2022). Canberra: AIHW.